Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke

Stroke

Volumn 45, Issue 11, 2014, Pages 3304-3310

  Urfer, Roman ^a   Moebius, Hans J ^b   Skoloudik, David ^c   Santamarina, Estevo ^d   Sato, Wakao ^a   Mita, Shiro ^a   Muir, Keith W ^e  

^a M's Science Corporation   (Japan)

^b Moebius Consult GmbH   (Switzerland)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trial; Randomized controlled trial; SA 4503; Stroke

Indexed keywords

CUTAMESINE; PLACEBO; CARBON; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ADULT; ARTICLE; BARTHEL INDEX; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RESPIRATORY FAILURE; STROKE PATIENT; TREATMENT DURATION; AGED; AGONISTS; CLINICAL TRIAL; CONVALESCENCE; DIAGNOSTIC USE; INTERNATIONAL COOPERATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARBON RADIOISOTOPES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PIPERAZINES; RECEPTORS, SIGMA; RECOVERY OF FUNCTION; STROKE; TIME FACTORS;

EID: 84922479757     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005835     Document Type: Article

References (27)

1. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009;10:861-872.
2. Pekna M, Pekny M, Nilsson M. Modulation of neural plasticity as a basis for stroke rehabilitation. Stroke. 2012;43:2819-2828.
3. Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain. 2011;134(pt 3):732-746.
4. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31:557-566.
5. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596-610.
6. Fujimoto M, Hayashi T, Urfer R, Mita S, Su TP. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse. 2012;66:630-639.
7. Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther. 2010;332:388-397.
8. Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci U S A. 2009;106:22468-22473.
9. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2011;15:557-577.
10. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol. 1996;306:271-279.
11. Carmichael ST. Themes and strategies for studying the biology of stroke recovery in the poststroke epoch. Stroke. 2008;39:1380-1388.
12. Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440:19-22.
13. Han J, Pollak J, Yang T, Siddiqui MR, Doyle KP, Taravosh-Lahn K, et al. Delayed administration of a small molecule tropomyosin-related kinase B ligand promotes recovery after hypoxic-ischemic stroke. Stroke. 2012;43:1918-1924.
14. Guidance for Industry-E6 Good Clinical Practice: Consolidated Guidance. http://www.fda.gov/downloads/Drugs/Guidances/ucm073122. pdf. United States of America Food and Drug Administration Web site. Published April 1996. Accessed August 10, 2014.
15. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
16. Rankin J. Cerebral vascular accidents in patients over the age of 60 II. Prognosis. Scott Med J. 1957;2:200-215.
17. Mahoney FI, Barthel D. Functional evaluation: The Barthel Index. MD State Med J. 1965;14:56-61.
18. van Marwijk HW, Wallace P, de Bock GH, Hermans J, Kaptein AA, Mulder JD. Evaluation of the feasibility, reliability and diagnostic value of shortened versions of the geriatric depression scale. Br J Gen Pract. 1995;45:195-199.
19. Bruno A, Saha C, Williams LS. Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure. J Stroke Cerebrovasc Dis. 2009;18:56-59.
20. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-130.
21. Cramer SC, Fitzpatrick C, Warren M, Hill MD, Brown D, Whitaker L, et al. The Beta-hCG+Erytropoietin in acute stroke (BETAS) study. A 3-center, single-dose, open-label, noncontrolled phase IIa safety trial. Stroke. 2010;41:927-931.
22. Cramer SC, Hill MD; REGENESIS Investigators. Study of NTx® -265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS Trial). International Stroke Conference, Los Angeles, 2011.
23. Ehrenreich H, Weissenhorn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al; Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
24. Schäbitz WR, Laage R, Vogt G, Koch W, Kollmar R, Schwab S, et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke. 2010;41:2545-2551.
25. Sprigg N, Bath PM, Zhao L, Willmot MR, Gray LJ, Walker MF, et al. Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: The Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke. 2006;37:2979-2983.
26. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647-e656.
27. Ringelstein EB, Thijs V, Norrving B, Chamorro A, Aichner F, Grond M, et al; AXIS 2 Investigators. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013;44:2681-2687.